From the Department of Medicine, Division of Cardiology, Birmingham Veteran Affairs Medical Center (L.J.D.), Division of Cardiovascular Disease, Department of Medicine (L.J.D.), and Department of Cell, Developmental and Integrative Biology (J.F.C.), University of Alabama at Birmingham; and Division of Surgical Sciences, Wake Forest University School of Medicine, Winston-Salem, NC (C.M.F.).
Circ Res. 2018 Jan 19;122(2):319-336. doi: 10.1161/CIRCRESAHA.117.310978.
Chymase is the most efficient Ang II (angiotensin II)-forming enzyme in the human body and has been implicated in a wide variety of human diseases that also implicate its many other protease actions. Largely thought to be the product of mast cells, the identification of other cellular sources including cardiac fibroblasts and vascular endothelial cells demonstrates a more widely dispersed production and distribution system in various tissues. Furthermore, newly emerging evidence for its intracellular presence in cardiomyocytes and smooth muscle cells opens an entirely new compartment of chymase-mediated actions that were previously thought to be limited to the extracellular space. This review illustrates how these multiple chymase-mediated mechanisms of action can explain the residual risk in clinical trials of cardiovascular disease using conventional renin-angiotensin system blockade.
糜酶是人体内生成血管紧张素 II(Angiotensin II)效率最高的酶,它与多种人类疾病相关,这些疾病也与糜酶的多种其他蛋白酶活性相关。人们普遍认为糜酶是肥大细胞的产物,但鉴定出的其他细胞来源,包括心脏成纤维细胞和血管内皮细胞,表明糜酶在各种组织中有更广泛的弥散产生和分布系统。此外,新近出现的证据表明糜酶在心肌细胞和平滑肌细胞中的细胞内存在,为以前认为仅限于细胞外空间的糜酶介导作用开辟了一个全新的领域。这篇综述说明了这些多种糜酶介导的作用机制如何能够解释使用传统肾素-血管紧张素系统阻断在心血管疾病临床试验中的残留风险。